{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-126550","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.563340+00:00","generated_at":"2026-05-29T05:35:19.116849+00:00","sec_items":["2.05","5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Carisma Therapeutics reduces workforce by 34%, terminates CFO, discontinues lead candidate CT-0525","bullets":["Reduction of 23 employees (34% of workforce); expects ~$2.7M in one-time termination costs, substantially complete by Q1 2025.","CFO Richard Morris terminated without cause effective Dec 31, 2024; entitled to 12 months base salary, target bonus, COBRA; retention option accelerated.","Discontinues lead product CT-0525 (HER2 solid tumor) due to competitive landscape; final patient already enrolled in Phase 1.","Revised plan focuses on in vivo mRNA/LNP CAR-M programs with Moderna, plus fibrosis, neurodegeneration, and other diseases; potential development of CT-1119.","Company expects to appoint a consultant as principal financial and accounting officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-126550","json":"https://secwatch.observer/filing/0001104659-24-126550.json","markdown":"https://secwatch.observer/filing/0001104659-24-126550.md","text":"https://secwatch.observer/filing/0001104659-24-126550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924126550/0001104659-24-126550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924126550/tm2430483d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:35:19.116849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}